Fact Based List:
Deborah L. Feinstein: Four design features of ACOs that raise red flags for antitrust agencies
Submitted by Charlene Ice on Fri, 07/25/2014 - 16:30
- preventing payers from steering patients to certain providers
- tying sales of the ACO’s services to the private payer’s purchase of other services from providers outside the ACO
- requiring exclusivity that discourages providers from contracting with payers outside the ACO
- restricting a payer’s ability to make available to enrollees information on cost, quality, efficiency, and performance
Notes: Deborah L. Feinstein is the Director of the Federal Trade Commission's Bureau of Competition. This list is from her presentation at the Fifth National ACO Summit.
Source: "Antitrust Enforcement in Health Care: Proscription, not Prescription," Fifth National Accountable Care Organization Summit – Washington, DC
Source URL: http://www.ftc.gov/system/files/documents/public_statements/...
List Ratings: |
Lists You Might Also Be Interested In
- Survey: When ACOs Will Have A Material Impact in my Market Place
- Becker's ASC Review: 50 Things to Know About the Proposed ACO Regulations
- Agenda Set for 9th Annual ACO Web Summit: November 8, 2018
- MedPAC: 4 Advantages of Prospective Assignment of ACO Beneficiaries
- Definitive Healthcare: Top 10 ACOs by Patient Population
Login or register to post comments